Characteristics of and therapeutic strategy for pulmonary typical carcinoid: a population-based study  

作　　者：Ying Cao Wen-Cang Gao Hong-Ye Zhu Cheng Yao 

机构地区：[1]Department of Medical Oncology,The Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,Zhejiang 310005,China.

出　　处：《Chinese Medical Journal》2021年第11期1385-1386,共2页中华医学杂志（英文版）

摘　　要：To the Editor:Pulmonary carcinoid(PC)is a rare well-differentiated neuroendocrine tumor that accounts for only approximately 2%of all malignant lung tumors.[1]PCs are further divided by malignancy into low-and intermediate-grade malignant tumors,namely typical(TC)and atypical carcinoid(AC).Because of the low morbidity,there is a paucity of data on TC based on a large population or randomized controlled trials.According to recent guidelines and consensus statements,lobectomy or other anatomic resection procedures and mediastinal lymph node dissection or sampling are the standard treatment for stage I–II and resectable stage IIIA disease,and adjuvant therapy is not recommended after complete resection;nevertheless,there is a lack of consensus on the treatment for unresectable stage III and metastatic disease,especially regarding the necessity of surgery and chemotherapy.

关 键 词：CARCINOID CHEMOTHERAPY LUNG 

分 类 号：R734.2[医药卫生—肿瘤]